H.R. 7853: PrEP Access and Coverage Act of 2026
The PrEP Access and Coverage Act of 2026 focuses on improving access to HIV prevention methods. It mandates that insurance policies must cover prescribed HIV prevention drugs, known as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), along with related services. Importantly, these provisions are to be covered without any out-of-pocket costs to the patients, effectively eliminating cost-sharing for these vital preventive services.
Funding and Reporting Requirements
The bill specifies that there will be funding allocated for the PrEP program from 2026 to 2030. It also requires annual reports for a period of five years that evaluate the effectiveness of grants provided for these PrEP programs. The reporting is intended to assess how well the program is performing in achieving its goals of reducing HIV transmission and improving access to preventive care.
Legal and Compliance Provisions
To ensure adherence to the requirements set forth in the legislation, the bill grants individuals the right to sue if their insurance companies do not comply with the coverage mandates. Additionally, it establishes monitoring and reporting duties for various government Secretaries to oversee health coverage compliance and ensure that the objectives of the legislation are met.
Public Awareness and Education
The bill places a strong emphasis on promoting public awareness and education about the use and availability of PrEP and PEP. This initiative aims to inform the public about these preventive measures, encouraging their uptake and fostering a greater understanding of HIV prevention strategies.
Overall Impact
In summary, the PrEP Access and Coverage Act of 2026 seeks to make HIV prevention more accessible and streamlined by mandating comprehensive insurance coverage without cost-sharing, providing necessary funding and evaluation mechanisms, and promoting education to ensure that more individuals are aware of the available prevention methods.
Relevant Companies
- GILD - Gilead Sciences, a leading developer of PrEP drugs like Truvada and Descovy, may see impacts on sales and market dynamics due to increased access facilitated by the bill.
- VRTX - Vertex Pharmaceuticals, which is involved in health solutions related to HIV, might also experience changes in demand and market response as awareness and accessibility increase.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
3 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Mar. 05, 2026 | Introduced in House |
| Mar. 05, 2026 | Referred to the Committee on Energy and Commerce, and in addition to the Committees on Oversight and Government Reform, Ways and Means, Veterans' Affairs, Armed Services, Natural Resources, Financial Services, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
